Cargando…

The “7+3” regimen in acute myeloid leukemia

Detalles Bibliográficos
Autor principal: Rowe, Jacob M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719100/
https://www.ncbi.nlm.nih.gov/pubmed/34985228
http://dx.doi.org/10.3324/haematol.2021.280161
_version_ 1784624868304617472
author Rowe, Jacob M.
author_facet Rowe, Jacob M.
author_sort Rowe, Jacob M.
collection PubMed
description
format Online
Article
Text
id pubmed-8719100
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Fondazione Ferrata Storti
record_format MEDLINE/PubMed
spelling pubmed-87191002022-01-14 The “7+3” regimen in acute myeloid leukemia Rowe, Jacob M. Haematologica Landmark Papers in Hematology Fondazione Ferrata Storti 2022-01-01 /pmc/articles/PMC8719100/ /pubmed/34985228 http://dx.doi.org/10.3324/haematol.2021.280161 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Landmark Papers in Hematology
Rowe, Jacob M.
The “7+3” regimen in acute myeloid leukemia
title The “7+3” regimen in acute myeloid leukemia
title_full The “7+3” regimen in acute myeloid leukemia
title_fullStr The “7+3” regimen in acute myeloid leukemia
title_full_unstemmed The “7+3” regimen in acute myeloid leukemia
title_short The “7+3” regimen in acute myeloid leukemia
title_sort “7+3” regimen in acute myeloid leukemia
topic Landmark Papers in Hematology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719100/
https://www.ncbi.nlm.nih.gov/pubmed/34985228
http://dx.doi.org/10.3324/haematol.2021.280161
work_keys_str_mv AT rowejacobm the73regimeninacutemyeloidleukemia
AT rowejacobm 73regimeninacutemyeloidleukemia